UNLABELLED: RNA-binding proteins (RBPs) play a major role in the control of messenger RNA (mRNA) turnover and translation rates. We examined the role of the RBP, human antigen R (HuR), during cholestatic liver injury and hepatic stellate cell (HSC) activation. HuR silencing attenuated fibrosis development in vivo after BDL, reducing liver damage, oxidative stress, inflammation, and collagen and alpha smooth muscle actin (α-SMA) expression. HuR expression increased in activated HSCs from bile duct ligation mice and during HSC activation in vitro, and HuR silencing markedly reduced HSC activation. HuR regulated platelet-derived growth factor (PDGF)-induced proliferation and migration and controlled the expression of several mRNAs involved in these processes (e.g., Actin, matrix metalloproteinase 9, and cyclin D1 and B1). These functions of HuR were linked to its abundance and cytoplasmic localization, controlled by PDGF, by extracellular signal-regulated kinases (ERK) and phosphatidylinositol 3-kinase activation as well as ERK/LKB1 (liver kinase B1) activation, respectively. More important, we identified the tumor suppressor, LKB1, as a novel downstream target of PDGF-induced ERK activation in HSCs. HuR also controlled transforming growth factor beta (TGF-β)-induced profibrogenic actions by regulating the expression of TGF-β, α-SMA, and p21. This was likely the result of an increased cytoplasmic localization of HuR, controlled by TGF-β-induced p38 mitogen-activated protein kinase activation. Finally, we found that HuR and LKB1 (Ser428) levels were highly expressed in activated HSCs in human cirrhotic samples. CONCLUSION: Our results show that HuR is important for the pathogenesis of liver fibrosis development in the cholestatic injury model, for HSC activation, and for the response of activated HSC to PDGF and TGF-β.
UNLABELLED: RNA-binding proteins (RBPs) play a major role in the control of messenger RNA (mRNA) turnover and translation rates. We examined the role of the RBP, human antigen R (HuR), during cholestatic liver injury and hepatic stellate cell (HSC) activation. HuR silencing attenuated fibrosis development in vivo after BDL, reducing liver damage, oxidative stress, inflammation, and collagen and alpha smooth muscle actin (α-SMA) expression. HuR expression increased in activated HSCs from bile duct ligation mice and during HSC activation in vitro, and HuR silencing markedly reduced HSC activation. HuR regulated platelet-derived growth factor (PDGF)-induced proliferation and migration and controlled the expression of several mRNAs involved in these processes (e.g., Actin, matrix metalloproteinase 9, and cyclin D1 and B1). These functions of HuR were linked to its abundance and cytoplasmic localization, controlled by PDGF, by extracellular signal-regulated kinases (ERK) and phosphatidylinositol 3-kinase activation as well as ERK/LKB1 (liver kinase B1) activation, respectively. More important, we identified the tumor suppressor, LKB1, as a novel downstream target of PDGF-induced ERK activation in HSCs. HuR also controlled transforming growth factor beta (TGF-β)-induced profibrogenic actions by regulating the expression of TGF-β, α-SMA, and p21. This was likely the result of an increased cytoplasmic localization of HuR, controlled by TGF-β-induced p38 mitogen-activated protein kinase activation. Finally, we found that HuR and LKB1 (Ser428) levels were highly expressed in activated HSCs in human cirrhotic samples. CONCLUSION: Our results show that HuR is important for the pathogenesis of liver fibrosis development in the cholestatic injury model, for HSC activation, and for the response of activated HSC to PDGF and TGF-β.
Authors: F Marra; A Gentilini; M Pinzani; G G Choudhury; M Parola; H Herbst; M U Dianzani; G Laffi; H E Abboud; P Gentilini Journal: Gastroenterology Date: 1997-04 Impact factor: 22.682
Authors: Nabeel Bardeesy; Manisha Sinha; Aram F Hezel; Sabina Signoretti; Nathaniel A Hathaway; Norman E Sharpless; Massimo Loda; Daniel R Carrasco; Ronald A DePinho Journal: Nature Date: 2002-09-12 Impact factor: 49.962
Authors: Mercedes Vázquez-Chantada; David Fernández-Ramos; Nieves Embade; Nuria Martínez-Lopez; Marta Varela-Rey; Ashwin Woodhoo; Zigmund Luka; Conrad Wagner; Paul P Anglim; Richard H Finnell; Juan Caballería; Ite A Laird-Offringa; Myriam Gorospe; Shelly C Lu; José M Mato; M Luz Martínez-Chantar Journal: Gastroenterology Date: 2010-01-25 Impact factor: 22.682
Authors: Keane K Y Lai; Soo-Mi Kweon; Feng Chi; Edward Hwang; Yasuaki Kabe; Reiichi Higashiyama; Lan Qin; Rui Yan; Raymond P Wu; Keith Lai; Naoaki Fujii; Samuel French; Jun Xu; Jian-Ying Wang; Ramachandran Murali; Lopa Mishra; Ju-Seog Lee; James M Ntambi; Hidekazu Tsukamoto Journal: Gastroenterology Date: 2017-01-29 Impact factor: 22.682
Authors: A Aguado; C Rodríguez; S Martínez-Revelles; M S Avendaño; O Zhenyukh; M Orriols; J Martínez-González; M J Alonso; A M Briones; D A Dixon; M Salaices Journal: Br J Pharmacol Date: 2015-03-27 Impact factor: 8.739
Authors: Elena Arriazu; Marina Ruiz de Galarreta; Francisco Javier Cubero; Marta Varela-Rey; María Pilar Pérez de Obanos; Tung Ming Leung; Aritz Lopategi; Aitor Benedicto; Ioana Abraham-Enachescu; Natalia Nieto Journal: Antioxid Redox Signal Date: 2014-01-08 Impact factor: 8.401
Authors: Na Chang; Jingjing Ge; Lei Xiu; Zhongxin Zhao; Xianghui Duan; Lei Tian; Jieshi Xie; Lin Yang; Liying Li Journal: J Mol Med (Berl) Date: 2016-08-20 Impact factor: 4.599
Authors: Andrea Aguado; Thierry Fischer; Cristina Rodríguez; Adrian Manea; José Martínez-González; Rhian M Touyz; Raquel Hernanz; M Jesús Alonso; Dan A Dixon; Ana M Briones; Mercedes Salaices Journal: J Hypertens Date: 2016-02 Impact factor: 4.844